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Contractile forces are implicated in cell polarity and asymmetric division, but their contribution to cell fate is
unclear. In this issue ofCell StemCell, Shin et al. (2014) show that myosin-II isoforms sensematrix stiffness in
hematopoietic stem and progenitor cells, with polarized myosin-IIB promoting asymmetric self-renewal and
constitutive myosin-IIA activation promoting cytokine-triggered differentiation.Hematopoietic stem and progenitor cells
(HSPCs) maintain blood homeostasis via
a highly coordinated mechanism of self-
renewal and differentiation. An approach
to allow rational targeting of the balance
between stem cell self-renewal and differ-
entiation could be useful for increasing the
number of stem cells for transplantation
purposes or inducing differentiation of
HSPCs for effective recovery after chemo-
therapy in the clinic. Such approaches
may also bear therapeutic value in pre-
venting undesired self-renewal potential
in blood stem cell malignancies such as
leukemia or in rejuvenating reduced self-
renewal potential during the natural aging
process of HSPCs. A model explaining
the nature of HSPC divisions proposes
that the mode of stem cell division (sym-
metric versus asymmetric) may determine
the cell fate of the resulting two daughter
cells, with a symmetric division resulting
in daughter cells with similar regenerative
potential and an asymmetric division lead-
ing to daughter cells with a dissimilar
potential. Complex schemes for bone
marrow (BM) regulation of HSPC main-
tenance and differentiation have been
described (Doulatov et al., 2012). How-
ever, the molecular mechanisms that
determine whether HSPCs undergo
symmetric or asymmetric division and its
relationship with differentiation and self-
renewal, particularly under the physiolog-
ically relevant biophysical parameters of
the BM microenvironment that includes
vascular vessels, secreted cytokines,
and endosteum that ranges locally from
soft or rigid, need to be better defined.
Myosin-II proteins (MIIs) are non-
muscle, actin-based motor proteins un-derlying cortical tension and contractile
forces at the cleavage furrow during cyto-
kinesis of cell division (Ou et al., 2010).
In mesenchymal stem cells and HSPCs,
MIIs have been found to play a key role
in generating actomyosin forces in adhe-
sion and in sensing the stiffness of the
matrix environment (Engler et al., 2006;
Holst et al., 2010). In the blood system
it has been known that as granulocytes
differentiate they become less rigid to bet-
ter traffic from BM through the endothelial
barrier and into the circulation (Lichtman,
1970). Whether MII activities change dur-
ing hematopoiesis and if such changes
affect the fate of HSPCs are not clear.
The work by Shin et al. (2014) in this issue
of Cell Stem Cell now demonstrates that
contractile motor molecules, myosin-IIA
(MIIA) and myosin-IIB (MIIB), influence
HSPC fate choice and differentiation
through regulation of asymmetric cell
division.
By analyzing mass-spectrometry-cali-
brated intracellular flow cytometry of hu-
man CD34+ HSPCs, Shin et al. observed
different expression patterns and activ-
ities of MIIA and MIIB in the human
CD34+CD38 HSPCs: while both iso-
forms are present, MIIB, but not MIIA, is
strongly polarized on one side of the
HSPCs and is downregulated in differ-
entiated cells (Figure 1). Through manipu-
lation of fibronectin levels in cell culture
matrices, the authors showed that the po-
larity of MIIB is related to the stiffness of
matrix the cells are in contact with and
is sensitive to local mechanical stress.
siRNA-mediated knockdown of MIIB
caused a loss of polarity of the HSPCs
and a subsequent loss of asymmetricCell Stem Celsegregation of the stem/progenitor cell
marker CD34 during division, resulting in
more symmetric cell division that favors
self-renewal. Thus, MIIB controls HSPC
asymmetric division. To test the functional
importance in vivo, the authors also con-
ducted xenotransplantation studies in
NOD/SCID/IL-2Rg/ (NSG) mice. Trans-
planted human MIIB knockdown HSPCs
continued to proliferate but the amount
of differentiated blood cells dropped,
which is consistent with an enrichment
of the stem cell pool by increased sym-
metric division in the marrow at the
expense of differentiation.
MIIA is often the dominant MII isoform
and can influence MIIB function. Unlike
MIIB, MIIA activity, which is regulated
by dephosphorylation at residue S1943,
increases upon HSPC differentiation
(Figure 1). The authors further examined
regulation of MIIA activity in CD34+ cells
by environmental factors during cyto-
kine-mediated differentiation and found
a systematic reduction in pS1943-MIIA
upon treatment with Thrombopoietin and
Granulocyte-Colony Stimulating Factor,
but not Stem Cell Factor (SCF) alone.
CD34+ cell numbers were inversely corre-
lated with pS1943 levels, thus showing
that MIIA activity is modulated by cyto-
kines critical to differentiation. Suppres-
sion of pS1943-MIIA by a site-specific
peptide mimetic causes CD34+ cells to
fragment more often and divide more
slowly, indicating that high pS1943-MIIA
activity impacts cell mechanics and
limits cell division and hence differen-
tiation. Conversely, soft matrix increases
pS1943-MIIA in CD34+CD38 cells,
sensitizing them to matrix elasticity. Thel 14, January 2, 2014 ª2014 Elsevier Inc. 1
Figure 1. Myosin-II Isoforms Regulate HSPC Self-Renewal and Differentiation in Response
to Bone Marrow Matrix Mechanics and Cytokines
As contractile motors in cell division, MIIA and MIIB serve as sensors of matrix stiffness to affect cell
polarity and asymmetric division. MIIA is activated by endosteum-like stiff matrix during HSPC differenti-
ation by dephosphorylation at residue S1943 and maintains p53-dependent cell survival while the
differentially expressed and polarized MIIB is required for HSPC asymmetric division and self-renewal.
Transient inhibition of both myosin isoforms in culture depletes progenitors and enriches for stem cells.
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Previewsauthors also associated these findings
using a genetic mousemodel. Conditional
knockout of MIIA in mice leads to a
decrease in differentiated cell numbers
and promotes apoptosis of the defective
HSPCs in a p53-dependent manner.
Finally, reversible inhibition of both MII
isoforms using blebbistatin in combina-
tion with specific cytokines in culture
increases the prevalence of nondividing
stem cells while blocking the more
rapid division of progenies. The result-
ing outcome is enrichment for HSPCs,
implying a biophysical hierarchy of acto-
myosin forces in hematopoiesis.
The current studies reveal differential
expression and activity patterns of MIIA
and MIIB in hematopoiesis and implicate
MIIB in HSPCs asymmetric division and
an MIIB to MIIA switch as a key aspect
of hematopoietic differentiation. The ob-
servations raise the issue of how each of
the dynamic motors is regulated tran-
scriptionally and posttranslationally. To
this end, generic polarization of a protein
in hematopoietic cells may be predictive
of a role in asymmetric division (Li,
2013), but since MIIB’s role in physically
breaking the symmetry of cytokinesis
lies downstream of the matrix/cytokine2 Cell Stem Cell 14, January 2, 2014 ª2014 Esignaling cascade, it is tempting to spec-
ulate that the recently implicated Cdc42-
regulated cell polarity machinery in
HSPCs (Florian et al., 2012) may be
involved in mediating a signal flow from
BM matrix/cytokines to these mechanics
sensors. Further, because the underlying
signaling mechanisms from BM matrix
are quite complex and involve coordi-
nated sensing and action of signaling
nodal from multiple soluble factors
including SCF, canonical and noncanoni-
cal Wnt, TPO, TGFb, adhesion molecules
such as integrins and cadherins, and
chemokines such as SDF-1a, it will be a
challenge to sort out how MIIs function
in coordinating actomyosin, microtubule,
and cell division machineries to direct
the correct polarity and division asymme-
try. Recent advances allow manipulation
of single stem cell division ex vivo fol-
lowed by stringent functional evaluation
of cell fate in transplantated progenies
(Yamamoto et al., 2013), which may
enable addressing the mechanistic role
of MII for the mode of division directly in
individual HSPCs in response to matrix
stiffness and physiological stimuli. Finally,
the finding that suppression of MII iso-
forms promotes stem cell self-renewallsevier Inc.may be explored for HSPCs regeneration.
It is possible that an MIIB-specific inhibi-
tor that does not interfere with MIIA
could allow HSPCs to divide symmetri-
cally without affecting proliferation and
differentiation.
Whether the MII isoforms may play
similar roles in abnormal hematopoiesis
is a worthy area of future investigation.
Multiple BM-related pathologies such as
myelodysplasia syndrome and leukemia
involve profound alterations in BM micro-
environment including changes in matrix
stiffness and cytokine productions. It will
be interesting to see how MIIA and MIIB
activity, expression, or both are affected
during the course of HSPCs transforma-
tion, which is known to involve changes
in cell polarity and division symmetry
(Schroeder, 2007). Suppression of total
MII activity or one isoform could affect
the disease onset and progression
by modulating leukemia stem cell self-
renewal, survival, and maintenance in a
disease-unique marrow environment.
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